Trial Profile
A Multinational, Multicenter, Randomized, Parallel-group Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Assess Efficacy, Safety and Tolerability of Glatiramer Acetate Injection 40mg Compared to Placebo in a Double-blind Design
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms GALA
- Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries
- 26 May 2020 Primary endpoint has been met. (Annualized Rate of Confirmed Relapses Comparing Early Starters to Delayed Starters Estimated by Negative Binomial Regression)
- 26 May 2020 Results presented at the 6th Congress of the European Academy of Neurology
- 27 Apr 2018 According to a Teva Pharmaceutical media release, efficacy, safety and tolerability results up to 7-year were presented at the 70th Annual Meeting of the American Academy of Neurology (AAN) 2018.